Compare Adaptive Biotechnologies Corp (ADPT) vs Dow Inc (DOW) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs Dow Inc — how do they compare? Adaptive Biotechnologies Corp trades at $20.19 (market cap $3.33B), while Dow Inc trades at $29.22 (market cap $20.64B). The key difference: Dow Inc is far larger — about 6.2× Adaptive Biotechnologies Corp's market cap, and Dow Inc pays a 4.89% dividend while Adaptive Biotechnologies Corp pays none. Which is the better fit depends on your goals.
| ADPT | DOW | |
|---|---|---|
Market Cap | $3.33B | $20.64B |
Sector | Health | Basic Materials |
52-Week High | $22.37 | $41.87 |
52-Week Low | $10.24 | $20.65 |
Enterprise Value | $3.19B | $36.42B |
Dividend Yield | — | 4.89% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $20.82, down 1.75% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.40. The company announced a strategic separation of its MRD and Immune Medicine businesses in June 2026, alongside a $300 million convertible notes offering to enhance financial flexibility. Revenue grew to $277 million in 2025, though net losses persist at -$59.50 million, with improving margins and cash flow trends showing net positive cash generation of $22.37 million.
Outlook remains cautiously optimistic as the business split aims to unlock value, but execution risks and sustained profitability challenges pose headwinds. Analysts are predominantly bullish (64.71% buy ratings), citing growth in the clonoSEQ MRD segment, yet the stock faces volatility from high valuation multiples and insider selling activity.
DOW trades at $28.64, up 3.36% today, with a bearish technical signal despite recent earnings beats. The stock shows negative profitability with a net income margin of -7.24% and ROE of -17.85%, though valuation ratios like P/S of 0.5 appear modest. Cash flow trends indicate operational challenges, with 2025 operating cash flow at $1.03B down from prior years, while the company maintains a dividend payout.
Outlook remains cautious due to weak fundamentals and bearish technicals, but analyst consensus price target of $36.11 suggests 26% upside. Key risks include sustained negative margins and high debt levels, while potential catalysts hinge on cost-cutting effectiveness and market demand recovery.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About Dow Inc
Dow Inc is a diversified chemical manufacturing company. It combining science and technology to develop innovative solutions that are essential to human progress. Dow's portfolio is comprised of six global business units, organized into three operating segments: Packaging & Specialty Plastics, Industrial Intermediates & Infrastructure, and Performance Materials & Coatings.
Read more on DOW →
